An innovative transnational Mumbai based Pharmaceutical Company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and emerging markets of the world. The company aims to fight life threatening infectious diseases and to manufacture drugs of the highest social priority. Lupin is one of the world’s largest manufacturers of Tuberculosis drugs. Today the Company has significant market share in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy, Anti-TB and Cephalosporins segments. The manufacturing units of Lupin in India and Japan has got approval by international regulatory agencies like US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa. Lupin has its presence in more than 100 countries of the world.
10 years journey of Lupin pharma
Globally, Lupin is the 7th largest in terms of market capitalization and 9th largest in terms of sales in Generic drugs. It is the 3rd largest pharma company in India in terms of revenue.
Research and Development
1400 scientists are engaged in research and development program of the company headquartered in Lupin Research Park located near Pune.
- Generics Research
- Process Research
- Pharmaceutical Research
- Advanced Drug Delivery Systems (ADDS) Research
- Intellectual Property Management
- Novel Drug Discovery and Development (NDDD)
- Biotechnology Research
March 2016 Result Update
The revenue from operations for Mar 2016 came to 4181.16 crore reporting a growth of 17.58% QOQ and 35.83% YOY
Operating Profit 1222.82 crore, growth of 59% QOQ and 79% YOY
Net Profit 807.08 crore indicating a growth of 52% QOQ and 47.50% YOY.
Recent News of Lupin
The US Food and Drug Administration (FDA) today have given an all clear report recently to Lupin’s Mandideep unit which was earlier under observation from March 2016. That is a boost for the company since Mandideep unit contributes 15 – 20 percent of US revenues. According to Industry experts, overhang on Goa and few other plants of the Company will be removed very soon. 18 observations are pending from US FDA to get approval and clearance for GOA plant. The clearance will be crucial for Lupin.
Conclusion: The stock is trading at 1485 and 1435 is a good level for buying.
Lupin is one of the Top 500 Shares identified by Dynamic Research team at the end of every quarter out of 1700 Shares of NSE.
To get more information on Support and Resistance levels of the share, please visit Lupin Share Price Forecast.
Comments